Jingrong Jean Cui

This inventor holds 45 USPTO granted patents and 23 published patent applications, plus 7 CIPO patents and 13 EPO patents, primarily in Macrocyclic Compounds. Top assignees: Turning Point Therapeutics, Inc., Sugen Incorporated, Pfizer Corporation. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jingrong Jean Cui. Retrieved from https://idiyas.com/inventor/jingrong-jean-cui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 23)

% Patents Active = 71.1

CIPO Patents = 7 (Patent Applications = 20)

EPO Patents = 13 (Patent Applications = 37)

Average Co-Inventor Count = 5.2

ph-index = 12

Forward Citations = 406(Granted Patents)

Location History:

Albany, CA (US) (2005)
Foster City, CA (US) (2003 - 2006)
San Diego, CA (US) (2006 - 2024)

Company Filing History:

19 out of 19

Turning Point Therapeutics, Inc.

Tp Therapeutics, Inc.

patents

5. 2 out of 174

Agouron Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Macrocyclic Compounds

Protein Kinase Inhibitors

Combination Therapy

Chiral Diaryl Macrocycles

Polymorphs

Tropomyosin-related Kinase

Aminoheteroaryl Compounds

Enantiomerically Pure Compounds

Tetracyclic Compounds

Pyrazole Compounds

Triazolopyrazine Derivatives

Geometrically Restricted Compounds

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12606571 - Macrocyclic compounds and uses thereof (2026-04-21),

2. RE50634 - Diaryl macrocycles as modulators of protein kinases (2025-10-14),

3. 12404281 - Diaryl macrocycles as modulators of protein kinases (2025-09-02),

4. 12310968 - Chiral diaryl macrocycles and uses thereof (2025-05-27),

5. 12187739 - Diaryl macrocycle polymorph (2025-01-07),

6. 11981684 - Macrocyclic compounds and uses thereof (2024-05-14),

7. 11666574 - Combination therapy involving diaryl macrocyclic compounds (2023-06-06),

8. 11654145 - Combination therapy involving diaryl macrocyclic compounds (2023-05-23),

9. 11634433 - Macrocycles for use in treating disease (2023-04-25),

10. 11452725 - Chiral diaryl macrocycles and uses thereof (2022-09-27),

11. 11291667 - Combination therapy involving diaryl macrocyclic compounds (2022-04-05),

12. 11286265 - Macrocyclic compounds for treating disease (2022-03-29),

13. 11286264 - Macrocyclic compounds and uses thereof (2022-03-29),

14. 11155563 - Macrocyclic compounds and uses thereof (2021-10-26),

15. 11142533 - Macrocycles for use in treating disease (2021-10-12),

Title: The Innovative Journey of Jingrong Jean Cui

Introduction: Jingrong Jean Cui is a pioneering inventor based in San Diego, CA, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Jingrong Jean Cui holds several patents in the areas of artificial intelligence, machine learning, and biotechnology, showcasing her commitment to pushing the boundaries of technological advancement.

Career Highlights: With a background in computer science and engineering, Jingrong Jean Cui has worked with top research institutions and tech companies, leading teams to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout her career, Jingrong Jean Cui has collaborated with renowned scientists, engineers, and researchers, fostering a culture of innovation and knowledge-sharing that has led to numerous breakthroughs in the tech sector.

Conclusion: Jingrong Jean Cui's passion for innovation, coupled with her technical expertise and collaborative spirit, continues to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.